Barclays PLC Analysts Give Illumina Inc. (ILMN) a $142.00 Price Target
Barclays PLC set a $142.00 price objective on Illumina Inc. (NASDAQ:ILMN) in a research note released on Tuesday morning. The firm currently has a an equal weight rating on the life sciences company’s stock.
Several other analysts also recently weighed in on ILMN. CL King started coverage on shares of Illumina in a research report on Tuesday, June 21st. They issued a buy rating and a $165.00 price objective on the stock. Cantor Fitzgerald reiterated a hold rating on shares of Illumina in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Illumina from a sell rating to a hold rating in a research report on Monday, July 4th. Morgan Stanley downgraded shares of Illumina from an equal weight rating to an underweight rating and cut their price objective for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Finally, Piper Jaffray Cos. restated an overweight rating and set a $161.00 price target on shares of Illumina in a research report on Friday, July 15th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $156.88.
Shares of Illumina (NASDAQ:ILMN) opened at 138.31 on Tuesday. The stock has a 50 day moving average of $172.04 and a 200 day moving average of $156.15. The firm has a market capitalization of $20.28 billion, a price-to-earnings ratio of 47.37 and a beta of 0.47. Illumina has a 52-week low of $127.10 and a 52-week high of $196.47.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.13. The firm had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. Illumina’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm posted $0.80 EPS. On average, analysts predict that Illumina will post $3.53 EPS for the current fiscal year.
In other news, Director Jay T. Flatley sold 10,000 shares of the business’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $150.00, for a total value of $1,500,000.00. Following the completion of the sale, the director now directly owns 498,061 shares in the company, valued at $74,709,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction on Friday, October 7th. The stock was sold at an average price of $184.36, for a total transaction of $110,616.00. Following the completion of the sale, the director now owns 17,065 shares of the company’s stock, valued at $3,146,103.40. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. Physicians Financial Services Inc. boosted its stake in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Illumina during the second quarter worth $112,000. Ropes Wealth Advisors LLC boosted its stake in shares of Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its stake in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the last quarter. Institutional investors and hedge funds own 95.22% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.